Fujisawa, Kanagawa, May 28, 2018 – FIMECS, Inc. a private biotech creating a new class of drugs based on protein degradation, today announced that Yusuke Tominari, Ph.D., Chief Executive Officer and Chief Scientific Officer of FIMECS, make a corporate pitch at Start-Up Stadium in 2018 BIO on Monday, June 4, 2018 at 1:45pm ET in Boston, MA. For more information please visit http://convention.bio.org/startup/.
FIMECS, Inc. is a private biotech focusing on creating a new class of drugs based on disease relevant protein degradation. By integrating proprietary E3 ligase binder with molecule-designing capability, the company is developing proprietary therapeutic programs to rapidly induce the degradation of targeted proteins along with “RaPPIDS™” platform. Utilizing our drug discovery platform to internal and collaboration projects, the company seeks to provide life-saving medicine to patients all over the world. https://www.fimecs.com/eng/
FIMECS Media and Investor Contact
Yusuke Kohno, CFO and VP of corporate development